Neuroendocrine tumors: A European view

https://doi.org/10.1016/0002-9343(86)90581-4Get rights and content

Abstract

A center in Belfast, Northern Ireland, has established a register for tumors of the gastroenteropancreatic endocrine system. Carcinoid tumors occur most frequently. Of the non-carcinoid tumors, insulinomas, gastrinomas, and unknown types have the highest incidence, with other types being extremely rare. The potentially remediable nature of the tumors is stressed, and frequently a good quality of life can be experienced even in the presence of metastatic disease. The syndromes are probably underdiagnosed as they present with clinical features for which there are more common explanations, and appropriate diagnostic methods are therefore not used. The management of the syndromes is reviewed with particular emphasis on the treatment of patients with inoperable disease. Histamine (H2)-receptor antagonist therapy has made an impact in Zollinger-Ellison syndrome, and streptozotocin and somatostatin analogues can control tumor growth and endocrine syndromes, respectively.

References (27)

  • LH Abdullah et al.

    Substance P-like immunoreactivity in carcinoid tumours (abstr)

    Regul Pept

    (1983)
  • AJ Edis et al.

    Insulinoma: current diagnosis and surgical management

    Curr Probl Surg

    (1976)
  • CF Johnston et al.

    MEA type I gastrinomas are extrapancreatic (abstr)

    Regul Pept

    (1984)
  • KD Buchanan

    Gut hormones and gut endocrine tumour syndromes

    Br J Hosp Med

    (1980)
  • TL Kennedy et al.

    Endocrine system

  • KD Buchanan et al.

    The incidence of gut endocrine tumours in Ireland (abstr)

    Dig Dis Sci

    (1984)
  • RGP Watson et al.

    Frequency of gastrointestinal endocrine tumours in Northern Ireland

    Gut

    (1986)
  • MMT O'Hare et al.

    Characterisation of immunoreactive forms of pancreatic polypeptide (PP) in islet cell tumours

    Cancer

    (1985)
  • AB Atkinson et al.

    Insulinomas in N. Ireland 1960–1980-review of 16 cases

    Ulster Med J

    (1981)
  • MMT O'Hare et al.

    Pancreatic polypeptide (PP): a potential marker for carcinoid tumours (abstr)

    Dig Dis Sci

    (1984)
  • KD Buchanan et al.

    Pancreatic polypeptide (PP) levels may be an indicator of responsiveness to streptozotocin in gastrointestinal (GI) endocrine tumours (abstr)

    Dig Dis Sci

    (1984)
  • JJ Fennelly et al.

    Metastatic pancreatic vipoma: a case report of clinical response following treatment with corticosteroids and actinomycin D

    Clin Oncology

    (1982)
  • KD Buchanan et al.

    Evaluation of SMS 201-995 in gastrointestinal APUDomas

    Scand J Gastroenterol

    (1986)
  • Cited by (144)

    • Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study

      2022, Cancer Epidemiology
      Citation Excerpt :

      Overall, 31% of our patients underwent acute or semi-acute surgery which led to the diagnosis of SI-NET which is in line with the above-mentioned Swedish study [5]. These results are in contrast with previous studies from the UK where almost none were diagnosed preoperatively [20,21]. Curative treatment of neuroendocrine tumors is exclusively surgical, whereas biotherapy with somatostatin analogues and interferon is good symptomatic therapy [1,2,17].

    • Proteins differentially expressed in human beta-cells-enriched pancreatic islet cultures and human insulinomas

      2013, Molecular and Cellular Endocrinology
      Citation Excerpt :

      These important differences in the cytokine-induced response in rodent and human beta-cells urge caution when we directly translate the research results obtained in rodents to the human disease etiology and therapy. Insulinomas are the most common pancreatic endocrine neoplasms, representing approximately 17% of all neuroendocrine tumors of the digestive tract (Buchanan et al., 1986), constituting rare tumors, with an incidence of four patients per million inhabitants a year (Boden, 1989; Oberg and Eriksson, 2005; Tucker et al., 2006). Most insulinomas originate in individuals with a mean age of 50 years, being usually small (less than 2 cm), solitary and almost always benign (more than 90% of cases) (Boden, 1989; Oberg and Eriksson, 2005; Proye, 1987).

    • Epidemiology of gastroenteropancreatic neuroendocrine tumours

      2012, Best Practice and Research: Clinical Gastroenterology
      Citation Excerpt :

      Other national cancer registries reporting GEP-NET incidence originate from Norway, Sweden, Ireland, Netherlands, Denmark, Scotland and the United Kingdom [10,11,20,21,28–31]. Some of these national registries report incidence for all NET (including bronchial) [29,30], or for all ‘carcinoids’ [20,21,31], while others report on incidence by anatomic site [10,11,28]. National registries dedicated to NET patients that are not population based, like those from Germany, France, Spain and recently from Italy are an important source of data on the epidemiology of GEP-NET, but unfortunately are unable to report on incidence rates of these tumours [13,16,19,22].

    View all citing articles on Scopus

    This work was supported by a grant from the Ulster Cancer Foundation.

    1

    Mr. John Collins is a Royal Victoria Hospital Research Fellow.

    View full text